GvHD Symposium

2019 Symposium

Registration for the symposium is now open

2019 8th Annual Graft vs. Host Disease Symposium
Friday, April 26th 2019
Cleveland Airport Marriott
4277 West 150th Street
Cleveland OH 44135

Hotel Booking Info:
Cleveland Airport Marriot
(complimentary parking & basic internet)
Last day to book: 4/15/19
Special group rate: $85.00 per night

Register Today

Hotel Booking

Symposium Agenda

GvHD national symposium

Innovative And Life-Changing Research Presentations

A Unique Conference

For Physicians, Health Care Professionals, And Survivors

This unique conference, which focuses on cutting edge research and new treatments, consists of two tracks: one designed for physicians and other health care professionals, and one for bone marrow transplant (BMT) survivors, their families and their caregivers.
Cowden Foundation

Our Partners

The Meredith A. Cowden Foundation is proud to have provided funding for research, primarily concerning Graft vs. Host Disease (GvHD). GvHD is the main contributor to mortality following bone marrow transplantations in patients with leukemia.

Cleveland Clinic Cancer Center

At Cleveland Clinic Cancer Center, part of the NCCN and NCI-designated Case Comprehensive Cancer Center, more than 450 highly skilled doctors, researchers, nurses and technicians care for thousands of patients each year. Cleveland Clinic Cancer Center unites clinicians and researchers in Taussig Cancer Institute and in Cleveland Clinic’s 26 other clinical and surgical institutes, as well as cancer specialists at our regional hospitals, health centers and at Cleveland Clinic Florida. Ranked No. 1 in Ohio and No. 7 in the U.S. by U.S. News & World Report, our cancer center provides a range of services to patients including clinical trials and internationally-recognized cancer research efforts ensuring patients have access to the latest advances in cancer treatment, as well as a range of support programs helping patients navigate the challenges associated with a cancer diagnosis. Cleveland Clinic Cancer Center 9500 Euclid Avenue, Cleveland, Ohio 44195 800.223.2273 https://my.clevelandclinic.org/departments/cancer

University Hospitals Seidman Cancer Center

University Hospitals Seidman Cancer Center, part of the Case Comprehensive Cancer Center, is dedicated to the innovative treatment and promising research in the fight against cancer through ongoing studies aimed at cancer treatment and prevention. One of only 41 Comprehensive Cancer Centers in the country designated by the National Cancer Institute (NCI), Seidman can offer cutting-edge treatments earlier than most other cancer centers. Our affiliation with Case Western Reserve University provides ongoing studies aimed at cancer treatment and prevention. Patients receive skilled care through our multidisciplinary team approach. Experts in surgery, medical oncology, radiation therapy, pathology, nursing, social work, and psychology work together to create a personalized treatment plan that meets physical, emotional and spiritual needs. Recognized by U.S. News and World Report as one of the top hospitals for cancer care in the country, the mission of Seidman Cancer Center is simple: to cure cancer University Hospitals Seidman Cancer Center at UH Cleveland Medical Center 11100 Euclid Ave Cleveland, OH 44106 216-844-3951 http://www.uhhospitals.org/seidman

Case Comprehensive Cancer Center

The Case Comprehensive Cancer Center (Case CCC) based at Case Western Reserve University (CWRU) is a partnership organization supporting all cancer-related research efforts at CWRU, University Hospitals Case Medical Center, and the Cleveland Clinic. Located in Cleveland, Ohio, the Case CCC is an NCI designated cancer center and serves the cancer research and clinical needs of an urban manufacturing and rural agricultural region containing 3.8 million people in Northern Ohio Campus Location: Wolstein Research Building, Suite 1422 2103 Cornell Road Cleveland, OH 44106 https://case.edu/cancer/
UPMC Hillman Cancer Centerlogo a partner of the cowden foundation GvHD research

UPMC Hillman Cancer Center

At UPMC Hillman Cancer Center, we’re committed to giving you the knowledge, inspiration, and specialty care you need to boldly face your cancer. Because no diagnosis should stop you from doing the things you love, or from living each day to the fullest. We are the region’s only comprehensive cancer center designated by the National Cancer Institute. And with more than 60 UPMC Hillman Cancer Center locations, you won’t have to travel far to receive world-class treatments backed by best practices and leading-edge protocols. Learn more about who we are and how we can help you. UPMC Hillman Cancer Center 5115 Centre Ave., Fourth Floor Pittsburgh, PA 15232 412-864-6600 http://hillman.upmc.com/

BMT Infonet

BMT InfoNet was the first patient advocacy organization in the U.S. devoted solely to serving transplant patients. Blood & Marrow Transplant Information Network (BMT InfoNet) is a leading advocacy organization for bone marrow, stem cell and cord blood transplant patients. Founded in 1990, BMT InfoNet has pioneered a vast array of services to help transplant patients make critical decisions throughout their transplant journey. BMT InfoNet 1548 Old Skokie Road, Suite 1 Highland Park, IL 60035 Toll Free: (888) 597-7674 www.bmtinfonet.org

nbmtLINK

Linking curing & caring from diagnosis through survivorship. The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.
  • Survivorship Resources
  • Original Publications
  • Informative Webcasts
  • Emmy Award-winning Video
  • Online Resource Library
  • Peer Support on Call
  • Telephone Education/Support Groups
20411 West 12 Mile Rd., Suite 108 Southfield, MI 48076 (800) 546-5268 (1-800-LINK-BMT) E-mail: info@nbmtlink.org www.nbmtlink.org
2019 GvHD Symposium

Planning Commitee

Steven Z. Pavletic, MD, MS

National Cancer Institute / NIH

Dr. Pavletic received his M.D. from the University of Zagreb School of Medicine in Croatia in 1979. In 1992, he completed a clinical fellowship in bone marrow transplantation at the Fred Hutchinson Cancer Research Center and University of Washington Medical School in Seattle, WA. In 1995, he completed his internal medicine residency at the University of Nebraska Medical Center (UNMC) in Omaha, NE, and completed his hematology and oncology fellowship in June 1997. Until October 2002, Dr. Pavletic served as the director of the Allogeneic Stem Cell Transplantation Program at UNMC. In 2002, Dr. Pavletic received an appointment at the National Cancer Institute (NCI) and an adjunct appointment at the National Institute for Arthritis and Musculoskeletal and Skin Diseases at NIH. Currently, he is the head of the Graft-versus-Host and Autoimmunity Unit in the Experimental Transplantation and Immunology Branch. In October 2006, Dr. Pavletic received the NCI Director’s award for his achievements in developing national and international consensus guidelines for clinical trials in chronic GVHD.

Matt Kalaycio, MD, FACP

Cleveland Clinic

Matt Kalaycio, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Institute. Dr. Kalaycio holds a joint appointment in Cleveland Clinic’s Transplant Center and is a Professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Board-certified in hematology, Dr. Kalaycio’s clinical interests are in leukemia and stem cell transplantation. Dr. Kalaycio has been published in numerous scientific publications including Bone Marrow Transplantation, Journal of Clinical Oncology, and Leukemia. He serves on the editorial board of Biology of Blood and Marrow Transplantation. He also is the editor of a book on leukemia and co-editor of a book on clinical malignant hematology. His research interests focus on testing new treatments for leukemia. Dr. Kalaycio received his degree from West Virginia University School of Medicine in Morgantown. He completed his residency in internal medicine at Mercy Hospital of Pittsburgh and fellowships in hematology and medical oncology and bone marrow transplantation at Cleveland Clinic.

Kenneth R. Cooke, MD

Johns Hopkins Kimmel Cancer Center

Dr. Cooke is Director of the Johns Hopkins Kimmel Cancer Center’s Pediatric Bone Marrow Transplantation Program. Prior to his appointment at Johns Hopkins, Dr. Cooke headed the Pediatric Blood and Marrow Transplantation Program at Rainbow Babies and Children’s Hospital, and University Hospitals Case Medical Center, in Cleveland, Ohio. He also co-directed the Hematologic Disorders Program of the Case Comprehensive Cancer Center at Case Western Reserve University. A nationally recognized transplantation immunology expert, Dr. Cooke focuses primarily on new strategies to prevent and treat graft-vs-host disease and lung complications following blood and bone marrow transplantation. His research efforts have been recognized by the Leukemia and Lymphoma Society and the American Society of Clinical Investigation. In addition to his younger patients, Dr. Cooke also cares for adolescents and young adults.

Marcos, de Lima, MD

UH Cleveland Medical Center

Marcos de Lima, MD, is Director of the Hematologic Malignancies and Stem Cell Transplant programs at University Hospitals Cleveland Medical Center. He is also Professor of Medicine at Case Western Reserve University. Prior to joining the UH Cleveland Medical Center staff in 2012, he served as Professor of Medicine, Department of Stem Cell Transplantation and Cellular Therapy at M.D. Anderson Cancer Center in Houston, Texas. Dr. de Lima earned his Medical Doctor and Master in Internal Medicine degrees at Federal University of Rio de Janeiro School of Medicine, Rio de Janiero, Brazil. He completed a fellowship in Medical Oncology at University of Texas, M.D Anderson Cancer Center, Houston, Texas. A dedicated researcher, Dr. de Lima has extensive experience in developing and conducting clinical trials in the context of stem cell transplantation for cancers beginning in blood-borne tissue, bone marrow or in the cells of the immune system. His research focuses on strategies to expand transplantation of blood stem cells from one patient to another and in the treatment and prevention of post-transplant leukemia relapse. Dr. de Lima has approximately 230 published manuscripts and has written chapters for nearly a dozen textbooks. He is currently the acute leukemia working group co-chair, Center for International Bone Marrow Transplant Research.

Hien Liu, MD

Moffitt Cancer Center

Dr. Hien Liu is Medical Director of the Apheresis Unit and an Associate Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr. Liu earned her MD from the University of Michigan Medical School. She completed an Internal Medicine Residency at Michigan State University/Grand Rapids Medical Education and Research Center. Dr. Liu completed a Hematology/Oncology Fellowship at Cleveland Clinic Foundation, where she also served as Chief Fellow. Prior to joining Moffitt, Dr. Liu was an Assistant Professor at Cleveland Clinic Lerner College of Medicine and Associate Member at Case Comprehensive Cancer Center, Cleveland, Ohio. Dr. Liu is an experienced blood and marrow transplant physician, specializing in autologous and allogeneic transplant for lymphoid malignancies, as well as chimeric antigen receptor (CAR) T-cell therapy. Her clinical and research interests include peripheral blood stem cell mobilization strategies, leukapheresis for CAR T, and therapeutic photopheresis. Dr. Liu leads the Moffitt Apheresis Unit, where peripheral blood stem cell collections for hematopoietic stem cell transplant donors and cellular therapy patients are performed. In addition, she is part of the team of lymphoma physicians that see and perform CAR T-cell therapy for lymphoid cancers.

Annie, Im, MD

UPMC Hillman Cancer Center

Annie Im, MD, is an assistant professor of medicine at the University of Pittsburgh School of Medicine, and a hematologist/medical oncologist specializing and conducting research in hematologic malignancies (such as leukemia, lymphoma, and myeloma), drug development, stem cell transplantation, and graft-versus-host-disease. In addition, Dr. Im is responsible for the long term follow up of stem cell transplant recipients and the chronic graft-versus-host-disease clinic. Dr. Im is board-certified in internal medicine, hematology, and medical oncology. She received her medical degree from SUNY Stony Brook School of Medicine in Stony Brook, N.Y. Dr. Im completed both her residency in internal medicine and her hematology/oncology fellowship at UPMC. Dr. Im is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Society of Blood and Marrow Transplantation.

Betty Hamilton, MD

Cleveland Clinic Lerner College of Medicine

Betty Ky Hamilton is the Associate Director of the Blood and Marrow Transplant Program and Assistant Professor of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Hamilton received her medical degree from the University of Chicago and internal medicine residency training at the Hospital of the University of Pennsylvania. She completed her hematology/oncology fellowship at the Cleveland Clinic and subsequently joined as a Staff Physician in the Department of Hematology and Medical Oncology. Dr. Hamilton’s clinical and research interests focus on the treatment of hematologic malignancies with allogeneic hematopoietic cell transplantation; and improving outcomes post-allogeneic hematopoietic cell treatment, specifically in graft-versus-host disease and long-term follow up and survivorship.

2019 Symposium Speakers

KEYNOTE: Joseph H. Antin, MD
Dana Farber Cancer Insitute
Dr. Antin received his MD from Cornell University in 1978, and postgraduate training in hematology and medical oncology at DFCI and Brigham and Women’s Hospital. He subsequently served as director of the Bone Marrow Transplantation Service at BWH from 1987 to 1997. He now heads the Stem Cell Transplant Program of the Department of Medical Oncology at DFCI and BWH. He is a founding member and past president of the American Society of Blood and Marrow Transplantation and a past Chairman of the Steering Committee of the BMT Clinical Trial Network.

Oluwatosin (Tosin) Goje, MD
Cleveland Clinic
Oluwatosin Goje (Jaiyeoba), who leads the Reproductive Infectious Diseases Program at Cleveland Clinic, is an Obstetrician Gynecologist fellowship-trained in Infectious Diseases at the Medical University of South Carolina, Charleston, SC, one of four academic centers that offer this specialty training in North America.

Colleen Lance, MD
Cleveland Clinic
Colleen G. Lance, MD is a staff physician in the Sleep Disorders Center in the Neurological Institute, Cleveland Clinic. She serves as Medical Director for the Cleveland Clinic-Hillcrest Hospital sleep laboratory.
Dr. Lance earned her medical degree from Baylor College of Medicine in Houston, Texas. She completed Internal Medicine residency at the University of Texas Health Science Center at Houston, including a year as Chief Medical Resident. After practicing internal medicine in private practice and as a hospitalist, she returned for fellowship in Sleep Medicine at the University of Texas Health Science Center. During her fellowship, she received the Founder’s Award from the Southern Sleep Society for her research in sleep disordered breathing in bariatric patients. She is board certified in Sleep Medicine through the American Board of Internal Medicine and the American Board of Sleep Medicine.
Dr. Lance has practiced sleep medicine since 2001, including experience at the M.D. Anderson Cancer Center and the Memorial Hermann Hospital System in Houston, Texas. She has been an active member of the American Academy of Sleep Medicine and is currently serving on the Payor Policy and Review Committee. Also, she served as the President of the Texas Society of Sleep Professionals for 2 years. Her passions include the treatment of complex sleep disordered breathing, particularly with non-invasive ventilation for which she has lectured both regionally and nationally. She is currently working on research projects in sleep apnea in relation to male fertility, and the use of commercial sleep monitoring devices in the oncology patient population.

Navneet Majhail, MD
Cleveland Clinic
Dr Navneet Majhail is the Director of the Blood & Marrow Transplant Program at the Taussig Cancer Institute, Cleveland Clinic and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio. He is also the president-elect of the American Society for Blood and Marrow Transplantation. He specializes in the care of adult patients receiving blood and marrow transplantation. His research focuses on transplant outcomes, health services and health policy issues in blood and marrow transplantation and quality of life and late effects in transplant survivors.

Areej R. El-Jawahri, MD
Massachusetts General Hospital
Dr. El-Jawahri is an oncologist specializing in the care of patients with hematologic malignancies and those undergoing hematopoietic stem cell transplantation. Clinically, she takes care of patients with acute leukemia, myelodysplastic syndrome, chronic leukemias, lymphomas, and myelomas. Her research interests include investigating patient-reported outcomes, enhancing patient-centered decision-making interventions, and designing supportive care interventions to improve the care of patients with hematologic malignancies with a special emphasis on patients undergoing hematopoietic stem cell transplantation. Her research also explores models of health care delivery to improve patients’ quality of life and clinical outcomes. She is an active member of the MGH Cancer Outcomes Research Program (CORE). She will also leading efforts in building and developing the MGH Bone Marrow Transplantation Survivorship Program. She has led and conducted multiple clinical trials focusing on enhancing the experience and clinical outcomes of patients with hematologic malignancies.

Amanda Budai, MSW, LCSW
UPMC
Manager of Social Work
Amanda Budai, MSW, LCSW, earned her Bachelor’s degree in social work from Edinboro University and her Master’s degree in social work from University of Pittsburgh. She has been a clinical social worker at UPMC Cancer Center for 10 years working with patients and families with hematology malignancies, stem cell transplant, and most recently, CAR T therapy. In 2018, she was named Leukemia and Lymphoma Society Hematology-Oncology Social Worker of the Year by the Association of Oncology Social Work. In addition, she serves as a Social Work Board Member for Bone Marrow Foundation, and as a Social Work Continuing Education Committee Member for the National Marrow Donor Program.

John F DiPersio, MD, PhD
Washington University School of Medicine in St. Louis
My research focuses on fundamental and translational aspects of leukemia and stem cell biology. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking and clinical and translational programs in both leukemia/MDS and stem cell transplantation. My laboratory also utilizes unique mouse models of allogeneic stem cell transplantation to explore novel genetic and epigenetic interventions aimed at mitigating graft vs. host disease (GvHD) while maintaining graft vs. leukemia (GvL). I am also a PI of multiple clinical trials focused on the diagnosis and treatment of patients with hematologic malignancies or those undergoing allogeneic stem cell transplantation. As Deputy Director of the Siteman Cancer Center I oversee all clinical and basic science research in the cancer center and I am active as a mentor of trainees and junior faculty and oversee faculty recruitment and retention in the Division. My personal research has focused on the role of stem cell transplantation and novel targeted interventions to alter the natural history of AML and other hematological malignancies. These studies have utilized bench-to-bedside mechanistic and preclinical modeling studies followed by early phase clinical trials. They have focused on targeting key elements of the hematopoietic niche for optimal stem cell mobilization and chemosensitization, mitigating GvHD in T replete transplants, understanding the genomic alterations in de novo and relapsed AML and developing and testing in the clinic novel therapeutics and immunotherapeutics for the treatment of AML before and after stem cell transplantation.

Steven Z. Pavletic, MD, MS
National Cancer Institute / NIH
Dr. Pavletic received his M.D. from the University of Zagreb School of Medicine in Croatia in 1979. In 1992, he completed a clinical fellowship in bone marrow transplantation at the Fred Hutchinson Cancer Research Center and University of Washington Medical School in Seattle, WA. In 1995, he completed his internal medicine residency at the University of Nebraska Medical Center (UNMC) in Omaha, NE, and completed his hematology and oncology fellowship in June 1997. Until October 2002, Dr. Pavletic served as the director of the Allogeneic Stem Cell Transplantation Program at UNMC. In 2002, Dr. Pavletic received an appointment at the National Cancer Institute (NCI) and an adjunct appointment at the National Institute for Arthritis and Musculoskeletal and Skin Diseases at NIH. Currently, he is the head of the Graft-versus-Host and Autoimmunity Unit in the Experimental Transplantation and Immunology Branch. In October 2006, Dr. Pavletic received the NCI Director’s award for his achievements in developing national and international consensus guidelines for clinical trials in chronic GVHD.

Madan Jagasia, MD
Vanderbilt University Medical Center
Associate Professor of Medicine
Chief, Section of Hematology-Stem Cell Transplant
Director, Outpatient Transplant Program

Dr. Jagasia is an integral part of the long-term transplant clinic with a singular focus on delivering efficient and effective care to the transplant patient. His primary research interest is graft-versus-host disease (GVHD), an immune complication of allogeneic stem cell transplantation.
As a clinical investigator, he is actively trying to identify non-HLA genetic factors that predict development of both acute and chronic GVHD. The development of biomarkers that predict for type of organs affected with GVHD along with response to therapy is an important aspect of his research. He is actively involved in clinical trials targeting various manifestations of chronic GVHD, and is the site principal investigator for the national chronic GVHD consortium.
Dr. Jagasia received his MBBS from King Edward Memorial College in Mumbai, India. He received his fellowship training at Vanderbilt University in hematology-oncology. He pursued his Masters of Science in Clinical Investigation at Vanderbilt from 2004-2006.
Dr. Jagasia has authored and co-authored more than 80 research articles in peer reviewed-journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He has served as a reviewer for many of these journals. He is a member of the GVHD and Leukemia working committees for the of International Blood and Marrow Transplant Center.

Michael Pulsipher, MD
Children Hospital Los Angeles
Dr. Pulsipher joined the Children’s Center for Cancer and Blood Diseases as the Head of the Section of Blood and Marrow Transplantation (BMT) and as BMT Clinical Research Chair in 2015. He is currently group chair of the Pediatric Blood and Marrow Transplant Consortium – an 80-member international clinical trials group—and is recognized as a leading influence in the field of pediatric BMT. He is currently principal or co-principal investigator on six national, multi-center studies and a co-investigator on multiple additional clinical trials. Dr. Pulsipher has authored more than 180 articles in peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Journal of Clinical Investigation, Blood, and Nature Genetics. He has also written twelve book chapters and presented widely at national and international conferences.
Clinical Interests
Dr. Pulsipher performs allogeneic and autologous transplantation for a wide variety of cancers, bone marrow disorders, and genetic diseases. He has significant expertise in allogeneic transplantation for acute leukemias, especially ALL, where he has run national research trials and published extensively. Another area Dr. Pulsipher is interested in is reducing toxicity approaches to transplantation of non-malignant disorders, and he is running national research protocols for patients with immunodeficiencies, HLH, and bone marrow failure disorders, specifically severe aplastic anemia. Finally, Dr. Pulsipher has become a national leader in cell therapy research and has organized or chaired national trials testing CAR T-cells and Viral Specific T-cells.

Jennifer Holter-Chakrabarty, MD
Stephenson Cancer Center
Jennifer Holter-Chakrabarty, MD is an associate professor of medicine in the section of hematology/oncology. She is also an adjunct associate professor of radiation oncology and holds the Inasmuch Foundation Chair in Cancer Screening, Education, and Outreach.
A lifelong Sooner, Jennifer received her Bachelor of Zoology with distinction from the University of Oklahoma. Dr. Holter attended medical school, residency, and fellowship at the University of Oklahoma. She is one of several active bone marrow transplant physicians at the Stephenson Cancer Center.
In education, she is a member of the Admission Board Committee, and will serve as chair for a three-year term starting in July 2014.
Her research interests include leukemia, transplantation, and imaging of marrow failure syndromes. In these endeavors, she has been funded locally and has collaborated with the National Cancer Institute to move her bench work to the bedside. She is currently the lead investigator at the Stephenson Cancer Center for a “Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution following Allogeneic Transplantation in Post-pubertal Children and Adults with Molecular Imaging Evaluation.”
Dr. Holter strongly believes in training the next generation of medical and research professionals, guaranteeing excellence in oncology care for Oklahoma in the future.

Marcel R. M. van den Brink, MD, PhD
Memorial Sloan Kettering Cancer Center
Physician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation. His expertise is in allogeneic (donor-provided) blood stem cell transplantation for adult cancer patients. Allogeneic hematopoietic stem cell transplantation (HSCT) is a therapy for a variety of malignancies, including leukemias, lymphomas and myeloma. Several complications limit its use including relapse of malignancy, graft versus host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation – all of which can lead to increased morbidity and mortality after allo-HSCT. His laboratory uses murine HSCT models to study clinically important problems in HSCT and to test novel therapeutic strategies which can be translated into clinical practice. Van den Brink’s major projects include strategies to enhance post-transplant immune reconstitution, the role of T cells in graft-versus-host-disease and graft-versus-tumor activity.

Support The 2019 Symposium

Become a Sponsor

The following sponsorship opportunities are currently available. Please contact Lyn Haselton, Event Coordinator, by emailing her at lynhaselton@gmail.com if you have questions or are interested in other opportunities not listed.

$10,000 –Symposium Host Sponsor

• Company recognition during the plenary session • Company logo will appear in symposium syllabus • Four complimentary meeting registrations

$7,500 – Speaker or Food/Beverage Sponsor

• Company recognition during the plenary session
• Company logo will appear in symposium syllabus
• Three complimentary meeting registrations

$5,000 – Plenary Session Sponsor

• Company recognition during the plenary session
• Company name recognition in symposium syllabus
• Two complimentary meeting registrations

$2,500 – Patient Scholarship Sponsor

• Company recognition during the plenary session
• Company name recognition in symposium syllabus
• One complimentary meeting registration

$2,000 – Symposium Video Sponsor

• Receive company recognition at beginning and end of the video. The video will be used for patient education and information only and will be available through the Meredith A. Cowden Foundation website and other BMT patient service organizations.
• One complimentary meeting registration

$1,500 – Exhibit Tables

2017 GvHD national symposium
The Meredith A. Cowden Foundation presented the 2017 National GvHD Health Symposium at the Grand Event Center in Columbus, OH on Friday, October 13th, 2017. This unique one-day conference consisted of two-tracks – one designed for physicians and other healthcare professionals and one for bone-marrow transplant (BMT) survivors, their families, and their caregivers. Both tracks focused on cutting-edge research and new treatments. Last year, over 200 people attended this unique event providing an opportunity for survivors, their families, and caregivers to interact with some of the world’s leading authorities on the cause, treatment and management of Graft vs. Host Disease, a complication that affects over 60% of bone marrow transplant patients. It is the only program of its kind in the United States focusing on this very specific complication. The 2017 Symposium • Provided a scientifically rigorous and clinically applicable program to medical providers • Provided programs for mid-level medical professionals and social workers who work with patients, survivors and their families • Presented programs specifically to the interests of BMT survivors, their families, and their caregivers • And, brought physicians and patients together to discuss issues, challenges, and successes of dealing with acute and chronic GvHD. For more information, contact Lyn Haselton at lynhaselton@gmail.com The Foundation would like to thank the Doctors and the other medical personnel that gave their time and knowledge to make the 2017 National GvHD Symposium a great success. We would also like to thank the more than 200 Doctors, medical personnel, patients, caregivers and families that attended. This was truly a day of learning for everyone who participated. THANK YOU!

Symposium Speakers Past

GvHD Symposium Speakers - Past
Jeffery J. Auletta, MD Assistant Professor Pediatric Hematology Oncology University Hospitals Case Medical Center Case Western Reserve University Kenneth R. Cooke, MD Ohio Eminent Scholar and Leonard P. Hannah Professor in Stem Cell and Regenerative Medicine National Center for Regenerative Medicine Case Western Reserve University Director, Pediatric BMT Program and The Multidisciplinary Initiative in GVHD University Hospitals Case Medical Center Ellen R. Frank, PhD Bone Marrow Transplant Survivor Senior Chair, Dana-Farber Patient Advisory Council Angie Giallourakis, PhD Adjunct Faculty, Special Education Cleveland State University Stanton L. Gerson, MD Professor of Hematological Oncology Director, NCI-designated Case Comprehensive Cancer Center Director, National Center for Regenerative Medicine (NCRM) Case Western Reserve University Director, Ireland Cancer Center University Hospitals Case Medical Center Mary Guay, PA Physician Assistant Hillman Cancer Center Matt E. Kalaycio, MD, FACP Professor, Cleveland Clinic Lerner College of Medicine at CWRU Staff, Hematologic Oncology and Blood Disorders Taussig Cancer Institute, Cleveland Clinic Mandy C. Leonard, BS, PharmD,BCPS Assistant Professor, Cleveland Clinic Lerner College of Medicine at CWRU Assistant Director, Drug Information Service, Cleveland Clinic George B. McDonald, MD Professor of Medicine University of Washington School of Medicine Head, Gastroenterology/Hepatology Section Fred Hutchinson Cancer Research Center Christy Paddon, LMSW Medical Social Worker Blood and Marrow Transplant Program Roswell Park Cancer Institute Steven Z. Pavletic, MD, MS Experimental Transplantation and Immunology Branch Staff Clinician National Cancer Institute Pavan Reddy, MD Associate Professor Department of Internal Medicine University of Michigan Sue Stewart Founder and CEO, Blood and Marrow Transplant Information Network Marcel R.M. van den Brink, MD, PhD Professor of Medicine and Immunology Weill Medical College, Cornell University Head, Division of Hematologic Oncology Memorial Sloan Kettering Cancer Center Daniel J. Weisdorf, MD Professor, Department of Medicine Masonic Cancer Center University of Minnesota Scientific Director, National Marrow Donor Program Catherine Bollard, MBChB, MD Associate Professor of Pediatrics, Medicine and Immunology Baylor College of Medicine Center for Cell and Gene Therapy Ryan N. Bookout, PharmD, BCOP Department of Blood and Marrow Transplantation H. Lee Moffi tt Cancer Center and Research Institute Anthony G. Brickner, PhD Assistant Professor of Medicine Immunology and Clinical and Translational Science University of Pittsburgh Cancer Institute Paul Carpenter, MBBS Associate Professor Department of Pediatrics Fred Hutchinson Cancer Research Center Stanton L. Gerson, MD Professor of Medicine Division of Hematology and Oncology Director, Case Comprehensive Cancer Center Case Western Reserve University SOM Director, Seidman Cancer Center University Hospitals Case Medical Center Flora Hoodin, PhD Professor, Department of Psychology Eastern Michigan University Adjunct Clinical Associate Professor Department of Psychiatry University of Michigan Hillard M. Lazarus, MD Professor of Medicine Division of Hematology and Oncology Case Western Reserve University SOM Chair, Cancer IRB University Hospitals Case Medical Center Lindsay Maurath, MS Outpatient Dietitian Cleveland Clinic Robert S. Negrin, MD Professor of Medicine Medical Director, Clinical Bone Marrow Transplantation Laboratory Division Chief, Blood and Marrow Transplantation Program Stanford University Joseph C. Noreika, MD Excellence in Eyecare Inc., Medina, OH Consulting Staff Summa Wadsworth-Rittman Hospital Sophie Paczesny, MD, PhD Assistant Professor, Pediatrics and Communicable Diseases Blood and Marrow Transplant Program University of Michigan Gerard Socie, MD, PhD Professor and Head, Hematology / Transplantation Hospital Saint Louis, Paris, France Robert J. Soiffer, MD Chief, Division of Hematologic Malignancies Co-Chief, Stem Cell/Bone Marrow Transplantation Program Dana-Farber Cancer Institute Claudio Anasetti, MD Professor and Chair Department of Blood & Marrow Transplant H. Lee Moffi tt Cancer Center & Research Institute Kenneth R. Cooke, MD Ohio Eminent Scholar and Leonard C. Hanna Professor in Stem Cell and Regenerative Medicine Case Western Reserve University Director, Pediatric Blood and Marrow Transplantation Program Director, Multidisciplinary Initiative in Graft-vs-Host Disease University Hospitals Case Medical Center Corey S. Cutler, MD, MPH, FRCPC Assistant Professor Department of Medicine Harvard Medical School Dana-Farber Cancer Institute Tanya Edwards, MD Cleveland Clinic Matt Kalaycio, MD, FACP Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Director, Bone Marrow Transplant Program Taussig Cancer Institute, Cleveland Clinic Stanton L. Gerson, MD Professor of Medicine Division of Hematology and Oncology Director, Case Comprehensive Cancer Center Case Western Reserve University SOM Director, Seidman Cancer Center University Hospitals Case Medical Center Sandra Mitchell, PhD, CRNP Research Scientist, Outcomes Research Branch Nurse Practitioner NCI Chronic Graft-Versus-Host-Disease Clinic and Study Group William J. Murphy, PhD Professor and Vice Chair Department of Dermatology University of California – Davis Steven Pavletic, MD, MS Experimental Transplantation and Immunology Branch National Cancer Institute Effie Petersdorf, MD Professor, Department of Medicine University of Washington Attending Physician Seattle Cancer Care Alliance Stefanie Sarantopoulos, MD, PhD Assistant Professor Department of Medicine Division of Hematology/Oncology University of North Carolina Warren D. Shlomchik, MD Associate Professor Department of Medicine Smilow Cancer Hospital Yale School of Medicine Keren Stronach, MPH Health Care Navigator UCSF Comprehensive Cancer Center Keith M. Sullivan, MD Department of Medicine Division of Cellular Therapy Duke University Medical Center
2016, 2017, 2018, 2019

GvHD Symposium Sponsors

Case Comprehensive Cancer Center The Case Comprehensive Cancer Center (Case CCC) based at Case Western Reserve University (CWRU) is a partnership organization supporting all cancer-related research efforts at CWRU, University Hospitals Case Medical Center, and the Cleveland Clinic. Located in Cleveland, Ohio, the Case CCC serves the cancer research and clinical needs of an urban manufacturing and rural agricultural region containing 3.8 million people in Northern Ohio
Cleveland Clinic Taussig Cancer Institute Taussig Cancer Institute provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research. Cleveland Clinic is moving toward the forefront of the cancer drug discovery revolution and cancer research. Through cancer research, we have identified new molecules with anti-tumor effects, developed collaborative ties with biotechnology companies, begun training more young scientists and expanded our base of financial support. These bold steps in cancer research will result in discovery and application of new therapies to help us eliminate cancer as a significant cause of mortality.
University Hospitals Seidman Cancer Center University Hospitals Seidman Cancer Center, part of the Case Comprehensive Cancer Center, is dedicated to the innovative treatment and promising research in the fight against cancer through ongoing studies aimed at cancer treatment and prevention. One of only 41 Comprehensive Cancer Centers in the country designated by the National Cancer Institute (NCI), Seidman can offer cutting-edge treatments earlier than most other cancer centers. Our affiliation with Case Western Reserve University provides ongoing studies aimed at cancer treatment and prevention. Patients receive skilled care through our multidisciplinary team approach. Experts in surgery, medical oncology, radiation therapy, pathology, nursing, social work, and psychology work together to create a personalized treatment plan that meets physical, emotional and spiritual needs. Recognized by U.S. News and World Report as one of the top hospitals for cancer care in the country, the mission of Seidman Cancer Center is simple: to cure cancer

Other Sponsors

Acknowledgments

Grants Provided by Mallinckrodt Pharmaceuticals Exhibits Provided by AbbVie Amgen Avadim Technologies, Inc. Celgene Corportation Jazz Pharmaceuticals Pfizer, Inc. Pharmacyclics LLC and Janssen Biotech, Inc. Seattle Genetics Other Support Provided by Pharmacyclics LLC and Janssen Biotech, Inc. Acceptance of funding in support of this program does not constitute the endorsement of any product or manufacturer. Patient Resource Exhibitors BMTInfoNet Leukemia & Lymphoma Society Meredith A. Cowden Foundation National Marrow Donor Program nbmtLink

Pin It on Pinterest